| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Marek Jarema, Przemysław Bieńkowski, Janusz Heitzman, Tadeusz Parnowski, Janusz Rybakowsk. Paliperidone palmitate: effectiveness, safety, and the use for treatment of schizophrenia. Psychiatria polska. vol 51. issue 1. 2017-06-16. PMID:28455891. |
its efficacy in patients with schizophrenia was similar and sometimes even better than the efficacy of other long-acting drugs, such as risperidone or olanzapine. |
2017-06-16 |
2023-08-13 |
Not clear |
| Nina R Schooler, Stephen R Marder, K N R Chengappa, Georgios Petrides, Donna Ames, William C Wirshing, Marjorie McMeniman, Robert W Baker, Haranath Parepally, Daniel Umbricht, John M Kan. Clozapine and risperidone in moderately refractory schizophrenia: a 6-month randomized double-blind comparison. The Journal of clinical psychiatry. vol 77. issue 5. 2017-06-07. PMID:27035871. |
clozapine and risperidone in moderately refractory schizophrenia: a 6-month randomized double-blind comparison. |
2017-06-07 |
2023-08-13 |
Not clear |
| Yusuke Iwata, Shinichiro Nakajima, Fernando Caravaggio, Takefumi Suzuki, Hiroyuki Uchida, Eric Plitman, Jun Ku Chung, Wanna Mar, Philip Gerretsen, Bruce G Pollock, Benoit H Mulsant, Tarek K Rajji, David C Mamo, Ariel Graff-Guerrer. Threshold of Dopamine D2/3 Receptor Occupancy for Hyperprolactinemia in Older Patients With Schizophrenia. The Journal of clinical psychiatry. vol 77. issue 12. 2017-06-05. PMID:28086010. |
the present post hoc study included 42 clinically stable outpatients with schizophrenia (dsm-iv) (mean ± sd age = 60.2 ± 6.7 years) taking olanzapine or risperidone. |
2017-06-05 |
2023-08-13 |
human |
| Qijing Bo, Fang Dong, Xianbin Li, Zhimin Wang, Xin Ma, Chuanyue Wan. Prolactin related symptoms during risperidone maintenance treatment: results from a prospective, multicenter study of schizophrenia. BMC psychiatry. vol 16. issue 1. 2017-05-26. PMID:27829454. |
prolactin related symptoms during risperidone maintenance treatment: results from a prospective, multicenter study of schizophrenia. |
2017-05-26 |
2023-08-13 |
Not clear |
| Qijing Bo, Fang Dong, Xianbin Li, Zhimin Wang, Xin Ma, Chuanyue Wan. Prolactin related symptoms during risperidone maintenance treatment: results from a prospective, multicenter study of schizophrenia. BMC psychiatry. vol 16. issue 1. 2017-05-26. PMID:27829454. |
this study aimed to investigate prolactin related symptoms (prs) in individuals with schizophrenia during risperidone maintenance treatment for one year, as well as to identify the risk factors for prs. |
2017-05-26 |
2023-08-13 |
Not clear |
| Hitoshi Sakurai, Takefumi Suzuki, Robert R Bies, Bruce G Pollock, Masaru Mimura, Shitij Kapur, Hiroyuki Uchid. Increasing Versus Maintaining the Dose of Olanzapine or Risperidone in Schizophrenia Patients Who Did Not Respond to a Modest Dosage: A Double-Blind Randomized Controlled Trial. The Journal of clinical psychiatry. vol 77. issue 10. 2017-05-25. PMID:27788310. |
increasing versus maintaining the dose of olanzapine or risperidone in schizophrenia patients who did not respond to a modest dosage: a double-blind randomized controlled trial. |
2017-05-25 |
2023-08-13 |
Not clear |
| Wen-Yin Chen, Shih-Ku Li. Comparison of Subjective Experiences and Effectiveness of First-Generation Long-Acting Injectable Antipsychotics and Risperidone Long-Acting Injectables in Patients With Schizophrenia. Journal of clinical psychopharmacology. vol 36. issue 5. 2017-04-28. PMID:27580495. |
comparison of subjective experiences and effectiveness of first-generation long-acting injectable antipsychotics and risperidone long-acting injectables in patients with schizophrenia. |
2017-04-28 |
2023-08-13 |
Not clear |
| Wen-Yin Chen, Shih-Ku Li. Comparison of Subjective Experiences and Effectiveness of First-Generation Long-Acting Injectable Antipsychotics and Risperidone Long-Acting Injectables in Patients With Schizophrenia. Journal of clinical psychopharmacology. vol 36. issue 5. 2017-04-28. PMID:27580495. |
we conducted a cross-sectional study to compare the subjective experiences and clinical effects of first-generation long-acting injectable (fga-lai) antipsychotics with those of risperidone long-acting injectables (ris-lais) in 434 schizophrenia patients. |
2017-04-28 |
2023-08-13 |
Not clear |
| Hidenobu Suzuki, Hiroyuki Hibino, Yuichi Inoue, Atsuhiko Takay. Comparison of Treatment Retention Between Risperidone Long-Acting Injection and First-Generation Long-Acting Injections in Patients With Schizophrenia for 5 Years. Journal of clinical psychopharmacology. vol 36. issue 4. 2017-04-12. PMID:27300251. |
comparison of treatment retention between risperidone long-acting injection and first-generation long-acting injections in patients with schizophrenia for 5 years. |
2017-04-12 |
2023-08-13 |
Not clear |
| Aysun Kalenderoğlu, Mustafa Çeli. [Augmentation of Clozapine With Paliperidone in Schizophrenia Patients With Partial Response to Treatment: A Case Series]. Turk psikiyatri dergisi = Turkish journal of psychiatry. vol 27. issue 1. 2017-03-27. PMID:27369686. |
paliperidone is a risperidone metabolite and it has proven effectiveness in schizophrenia treatment. |
2017-03-27 |
2023-08-13 |
Not clear |
| Katarzyna Kamińska, Karolina Noworyta-Sokołowska, Alexandra Jurczak, Anna Górska, Zofia Rogóż, Krystyna Gołembiowsk. Risperidone and escitalopram co-administration: A potential treatment of schizophrenia symptoms with less side effects. Pharmacological reports : PR. vol 69. issue 1. 2017-03-23. PMID:27755991. |
risperidone and escitalopram co-administration: a potential treatment of schizophrenia symptoms with less side effects. |
2017-03-23 |
2023-08-13 |
rat |
| Katarzyna Kamińska, Karolina Noworyta-Sokołowska, Alexandra Jurczak, Anna Górska, Zofia Rogóż, Krystyna Gołembiowsk. Risperidone and escitalopram co-administration: A potential treatment of schizophrenia symptoms with less side effects. Pharmacological reports : PR. vol 69. issue 1. 2017-03-23. PMID:27755991. |
it was demonstrated that co-administration of risperidone and selective serotonin reuptake inhibitors alleviated depressive symptoms and cognitive dysfunction in animal models of schizophrenia. |
2017-03-23 |
2023-08-13 |
rat |
| M-R Nikbakhat, S Arabzadeh, A Zeinoddini, Z Khalili, F Rezaei, P Mohammadinejad, A Ghaleiha, S Akhondzade. Duloxetine Add-On to Risperidone for Treatment of Negative Symptoms in Patients with Stable Schizophrenia: Randomized Double-Blind Placebo-Controlled Study. Pharmacopsychiatry. vol 49. issue 4. 2017-03-03. PMID:26902281. |
duloxetine add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized double-blind placebo-controlled study. |
2017-03-03 |
2023-08-13 |
Not clear |
| Alladi Charan, Deepak Gopal Shewade, Ravi Philip Rajkumar, Adithan Chandrasekara. Relation between serum prolactin levels and antipsychotic response to risperidone in patients with schizophrenia. Psychiatry research. vol 240. 2017-02-21. PMID:27111215. |
relation between serum prolactin levels and antipsychotic response to risperidone in patients with schizophrenia. |
2017-02-21 |
2023-08-13 |
Not clear |
| Alladi Charan, Deepak Gopal Shewade, Ravi Philip Rajkumar, Adithan Chandrasekara. Relation between serum prolactin levels and antipsychotic response to risperidone in patients with schizophrenia. Psychiatry research. vol 240. 2017-02-21. PMID:27111215. |
hyperprolactinemia is commonly seen in patients with schizophrenia on risperidone. |
2017-02-21 |
2023-08-13 |
Not clear |
| Wai Shing Tse, Ann Siu Wah Wong, Fu Chan, Alfred Hin Tat Pang, Alyson Jane Bond, Chau Kiu Raymond Cha. Different mechanisms of risperidone result in improved interpersonal trust, social engagement and cooperative behavior in patients with schizophrenia compared to trifluoperazine. Psychiatry and clinical neurosciences. vol 70. issue 5. 2017-02-13. PMID:26864920. |
different mechanisms of risperidone result in improved interpersonal trust, social engagement and cooperative behavior in patients with schizophrenia compared to trifluoperazine. |
2017-02-13 |
2023-08-13 |
Not clear |
| Hidenobu Suzuki, Hiroyuki Hibino, Yuichi Inoue, Atsuhiko Takay. Comparison of hospitalization risk before and after changing from risperidone long-acting injection to another long-acting injection or oral antipsychotic in patients with schizophrenia: Mirror-image study. Psychiatry and clinical neurosciences. vol 70. issue 8. 2017-02-13. PMID:27233756. |
comparison of hospitalization risk before and after changing from risperidone long-acting injection to another long-acting injection or oral antipsychotic in patients with schizophrenia: mirror-image study. |
2017-02-13 |
2023-08-13 |
Not clear |
| Ranganath D Rattehalli, Sai Zhao, Bao Guo Li, Mahesh B Jayaram, Jun Xia, Stephanie Sampso. Risperidone versus placebo for schizophrenia. The Cochrane database of systematic reviews. vol 12. 2017-02-13. PMID:27977041. |
risperidone versus placebo for schizophrenia. |
2017-02-13 |
2023-08-13 |
Not clear |
| Mayu Onozato, Hiromi Nakazawa, Hitomi Hakariya, Miho Shishikura, Chihiro Nagashima, Katsuyuki Ishimaru, Tatsuya Sakamoto, Hideaki Iizuka, Hideaki Ichiba, Takeshi Fukushim. Effect of risperidone on plasma d-serine concentration in rats post-administered with d-serine. Life sciences. vol 158. 2017-02-08. PMID:27352936. |
risperidone (ris) is a second-generation antipsychotic (sga) used to treat patients with schizophrenia. |
2017-02-08 |
2023-08-13 |
rat |
| Reema Narayan, Mohan Singh, OmPrakash Ranjan, Yogendra Nayak, Sanjay Garg, Gopal V Shavi, Usha Y Naya. Development of risperidone liposomes for brain targeting through intranasal route. Life sciences. vol 163. 2017-02-01. PMID:27593571. |
the present paper is aimed at development of functionalized risperidone liposomes for brain targeting through nasal route for effective therapeutic management of schizophrenia. |
2017-02-01 |
2023-08-13 |
rat |